A carregar...

Intrinsic and Acquired Resistance to HER2-Targeted Therapies in HER2 Gene-Amplified Breast Cancer: Mechanisms and Clinical Implications

Approximately 25% of human breast cancers overexpress the HER2 (ErbB2) proto-oncogene, which confers a more aggressive tumor phenotype and associates with a poor prognosis in patients with this disease. Two approved therapies targeting HER2, the monoclonal antibody trastuzumab and the tyrosine kinas...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Rexer, Brent N., Arteaga, Carlos L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3394454/
https://ncbi.nlm.nih.gov/pubmed/22471661
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!